KCKyu Yong Cho

Kyu Yong Cho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kyu Yong Cho has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Akinobu Nakamura

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    21 shared publications
  • Hiroshi Nomoto

    Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine Asahikawa Medical University Asahikawa Hokkaido Japan

    17 shared publications
  • Hideaki Miyoshi

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

    16 shared publications
  • Hiraku Kameda

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    15 shared publications
  • Tatsuya Atsumi

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan

    13 shared publications
  • Aika Miya

    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    11 shared publications

Latest Publications

  • Open Access

    Central adiposity is associated with the severity and multiligamentous involvement of ossification of the posterior longitudinal ligament

    by Huohuo Xue, Tsutomu Endo, Yoshinao Koike, Ryo Fujita, Akinobu Nakamura, Kyu Yong Cho, Yuki Oe, M Alaa Terkawi, Masahiro Kanayama, Katsuhisa Yamada, et al.

    Ossification of the posterior longitudinal ligament (OPLL) is increasingly recognized as a metabolic ossification phenotype characterized by obesity-related abnormalities, particularly visceral adiposity. Although visceral fat has been implicated in the development of OPLL, its relationship with ossification severity and multiligamentous involvement remains unclear. This study aimed to examine whether anthropometric indices reflecting central adiposity show consistent associations with the burden of spinal ligament ossification. We retrospectively analyzed 252 individuals, including 163 patients with OPLL and 89 controls. Anthropometric indices—BMI and body roundness index (BRI)—were evaluated alongside CT-based measurements of visceral and subcutaneous fat areas. Ossification severity was quantified using a validated CT-based ossification index encompassing OPLL, ossification of the ligamentum flavum (OLF), ossification of the anterior longitudinal ligament (OALL), and ossification of the supra/interspinous ligaments (OSIL). Logistic regression, spline modeling, and sex-stratified analyses were performed. Patients with OPLL, particularly those with diffuse-type disease, exhibited significantly greater visceral adiposity and higher BMI and BRI values than controls. Both BMI and BRI were associated with the presence of diffuse OPLL, whereas their associations with localized OPLL were weaker. Nonlinear analyses showed that BMI was associated with ossification severity mainly within the lower BMI range, whereas BRI demonstrated generally linear associations across multiple ligamentous sites. These patterns were more evident in females. These findings suggest that anthropometric indices reflecting central adiposity may provide complementary information when evaluating the extent of spinal ligament ossification. While CT-derived visceral fat remains the direct measure of abdominal adiposity, indices, such as BRI, may offer additional context for understanding metabolic features associated with ossification burden in OPLL.

  • Open Access

    Effect of pemafibrate on LDL ‐cholesterol properties in type 2 diabetes and hypertriglyceridemia by lipid management status: PARM ‐ T2D post hoc analysis

    by Hiroya Kitsunai, Kenichi Kito, Kazuno Omori, Kyu Yong Cho, Akinobu Nakamura, Jun Takeuchi, So Nagai, Ichiro Sakuma, Hiroshi Nomoto

    Although pemafibrate attracts attention for reducing LDL‐C in patients with high baseline LDL‐C, its comprehensive effects remain unclear in patients with type 2 diabetes. This post hoc analysis of the PARM‐T2D study investigated the effects of pemafibrate on LDL‐C concentration and particle size in 156 subjects with type 2 diabetes and hypertriglyceridemia, categorized by baseline LDL‐C levels. While triglycerides and remnant lipoprotein cholesterol significantly improved across all groups over 52 weeks, the impact on LDL‐C was multifaceted and dependent on baseline status. In participants with low baseline LDL‐C, concentrations increased without a rise in ApoB, suggesting an improvement in particle size. Conversely, in those with high baseline LDL‐C, both LDL‐C and ApoB decreased, reflecting favorable modifications according to baseline LDL‐C control status. These findings suggest that pemafibrate exerts beneficial, status‐dependent effects on LDL‐C properties, potentially reducing cardiovascular risk by improving LDL particle quality and quantity in high‐risk patients with diabetes.

  • Open Access

    Pemafibrate Improves Lipid and Liver Metabolism in Adult GH Deficiency: A Prospective Observational Study

    by Hiroshi Iesaka, Kyu Yong Cho, So Nagai, Aika Miya, Hiraku Kameda, Hiroshi Nomoto, Akinobu Nakamura, Tatsuya Atsumi

    Context: The outcomes of pemafibrate administration on hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease associated with adult growth hormone deficiency (AGHD) are unknown. Objective: To evaluate the effects of pemafibrate on hypertriglyceridemia and liver parameters in AGHD in a real-world setting. Design: A prospective observational study (December 2019-August 2023). Setting: Two referral hospitals in Japan. Patients: Thirty-four consecutive Japanese patients with AGHD complicated with hypertriglyceridemia. Hypertriglyceridemia was defined using a fasting serum triglyceride (TG) concentration of ≥1.7 mmol/L or treated with lipid-lowering medication. Treatment: Patients were prescribed pemafibrate or continued conventional therapy for 24 weeks. Main Outcome Measure: The percentage reduction in fasting serum TG level between baseline and 24 weeks was evaluated. Hepatic parameters, including hepatic steatosis index (HSI) derived from aspartate aminotransferase, alanine aminotransferase, and body mass index, were also evaluated, along with other metabolic parameters. The Mann–Whitney U-test and Fisher's exact test were used to compare the change between groups. A multiple regression was performed to identify predictors of TG change. Results: The change in serum TG level was significantly larger in the pemafibrate group than that in the conventional group (median: −51.0% [interquartile range (IQR): −69.0% to −21.0%] vs −13.0% [IQR: −34.0% to 9.0%], P = .0138). HSI decreased after 24 weeks of pemafibrate. Relative TG change correlated with baseline body mass index [regression coefficient (β) .0463, P < .0001] and HSI (β .0645, P = .0107). Conclusion: Pemafibrate had beneficial effects on hypertriglyceridemia as well as liver metabolism of patients with AGHD. However, its efficacy was attenuated by obesity.

  • Open Access

    Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study

    by Yuki Oe, Hiroshi Nomoto, Kyu Yong Cho, Takashi Omori, Koki Nakamura, Akihiro Takahashi, Yuka Suzuki, Jyunpei Yoshikawa, Akiko Kato-Sato, Shin Furukawa, et al.

    Background: Tirzepatide (TZP) has demonstrated efficacy for glycemic control and weight loss in subjects with type 2 diabetes (T2D). However, previous clinical trials were not conducted under the treatment of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a background regimen nor were they limited to subjects with chronic kidney disease (CKD). Objectives: We evaluated the glycemic control of tirzepatide switching from conventional GLP-1 receptor agonists in subjects with T2D and CKD. Design: This was a prospective, two-arm, observational study performed at a single center. Methods: Eligible subjects were individuals with T2D and CKD who had been treated with dulaglutide for more than 3 months, with glycated hemoglobin (HbA1c) ⩾7.0%, and an estimated glomerular filtration rate ⩽60 mL/min/1.73 m 2 . Subjects who switched to tirzepatide (TZP group) and those who continued dulaglutide (Dula group) were observed over 6 months. The primary outcome was a change in HbA1c over 6 months between the groups. Additional metabolic parameters, including body weight and the urine albumin-creatinine ratio (UACR), were evaluated. Adverse events in the TZP group were also investigated. Results: Of the 55 participants, 48 completed the study (TZP group, n = 23; Dula group, n = 25). Tirzepatide significantly reduced HbA1c and body weight compared with the Dula group over 6 months (both p < 0.01). UACR levels remained stable in the TZP group throughout the study period and increased significantly in the Dula group ( p < 0.05). Gastrointestinal events and hypoglycemia were observed in the TZP group, and those subjects who suffered hypoglycemic symptoms were mostly insulin users. Conclusion: Tirzepatide might be an effective alternative treatment for subjects with T2D and CKD who did not achieve sufficient glycemic control with conventional GLP-1RAs, as well as preventing the progression of nephropathy. Trial registration: This study was registered with the University Hospital Medical Information Network (registration number UMIN 000051344, date: June 16, 2023). https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_his_list.cgi?recptno=R000058576


  • Open Access

    Effects of canagliflozin on brain natriuretic peptide levels in patients with type 2 diabetes on peritoneal dialysis in Japan: protocol for a multicentre, prospective, randomised controlled trial (CARD-PD trial)

    by Naoko Matsuoka, Daigo Nakazawa, Saori Nishio, Kyu Yong Cho, Tomochika Maoka, Nobuharu Kaneshima, Rie Yamamoto, Junya Yamamoto, Mamiko Shimamoto, Minoru Makita, et al.

    Introduction Patients with type 2 diabetes (T2D) undergoing dialysis exhibit a higher mortality rate compared with those with other conditions, primarily due to vascular complications including coronary artery disease, heart failure and stroke. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a type of drug for T2D, have reportedly decreased cardiovascular and renal events in patients with heart failure and chronic kidney disease, irrespective of diabetes presence. Nevertheless, the evidence supporting the use of SGLT2 inhibitors in patients undergoing dialysis has been limited. Our study aims to evaluate the impact of SGLT2 inhibitors on cardiovascular disease in individuals with T2D undergoing peritoneal dialysis (PD). Methods and analysis The CARD-PD study is a multicentre, prospective, randomised, open-label comparison trial of canagliflozin treatment in patients diagnosed with T2D undergoing PD. Eligible patients meeting the criteria for participation will be randomly assigned to either the canagliflozin treatment group (100 mg/day) or the control group (delayed-start canagliflozin group) for a duration of 6 months. We set a target of 18 participants in each group (a total of 36) based on sample size calculations from a previous report. Randomisation is performed using a web-based system, wherein patients are stratified by age, sex and plasma brain natriuretic peptide (BNP) concentrations at the baseline. The primary outcome measure is the plasma BNP levels after 6-month period. Following this initial phase, patients from both groups will continue to receive canagliflozin treatment (100 mg/day) in the following manner: (1) patients in the canagliflozin group will continue canagliflozin treatment for an additional 6 months, while (2) patients initially in the placebo arm will transition to canagliflozin treatment for an additional 12 months. Ethics and dissemination The Ethics Review Board of Hokkaido University Hospital (CRB no. 1180001) has approved the CARD-PD study protocol. The results will be disseminated in peer-reviewed journals and summaries will be presented at scientific conferences. Trial registration number Japan Registry of Clinical Trials (jRCT1011210022); pre-results.


  • Frequency and determinants of lipid management target achievement in primary prevention of cardiovascular disease in type 2 diabetes

    by Aika Miya, Akinobu Nakamura, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi

    Aims This study aimed to clarify the real-world status of lipid management in outpatients with type 2 diabetes (T2DM) following the 2022 revision of the Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases. It also aimed to evaluate characteristics associated with the failure to achieve management targets. Materials and Methods In this post-hoc analysis of a multicenter, cross-sectional study, we included Japanese outpatients with T2DM undergoing primary prevention of atherosclerotic cardiovascular diseases (ASCVD) who provided fasting blood samples. The frequency and determinants of achieving low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) targets were assessed. Results Among 223 participants with a mean age of 67 and mean HbA1c of 7.1%, 61 had no history of peripheral arterial disease, microvascular complications, or smoking. Out of the 223 participants, 64.1% (95% CI: 57.6–70.1%) achieved the LDL-C target. In multivariate logistic regression analysis, being female (odds ratio [OR] 3.139, P = 0.0011), having diabetic nephropathy (OR 2.868, P = 0.0021), smoking (OR 2.292, P = 0.0281), and non-use of statins (OR 4.857, P < 0.0001) were independently associated with non-achievement. For non-HDL-C, 65.6% (95% CI: 58.1%–70.6%) of patients met the target. Having diabetic neuropathy (OR 2.428, P = 0.0054), smoking (OR 2.008, P = 0.0478), and non-use of statins (OR 2.277, P = 0.0112) were identified as factors associated with non-achievement. Conclusions Low achievement rate of revised lipid management targets for ASCVD primary prevention in T2DM was unveiled. Assessing comorbidities, encouraging smoking cessation, and prioritizing statin use are considered.


  • Open Access

    Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report

    by Hiroshi Iesaka, Hiraku Kameda, Aika Miya, Hiroshi Nomoto, Kyu Yong Cho, Akinobu Nakamura, Takashige Abe, Nobuo Shinohara, Tatsuya Atsumi

    Rationale: The increasing use of immune checkpoint inhibitors (ICIs) for treating malignant tumors result in the concomitant rise of immune-related adverse events (irAEs). This case report may provide useful insight to understanding the etiology of ICI-induced hypophysitis, a severe irAE leading to potentially fatal secondary adrenal insufficiency. Patient concerns: An 81-year-old Japanese man was hospitalized for diabetic ketoacidosis following 4 courses of ICI combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma. Diagnosis: Insulin secretion was depleted, leading to diagnosis of fulminant type 1 diabetes. Adrenocorticotropic hormone (ACTH) and cortisol levels were very high (60.8 pmol/L and 1575 nmol/L, respectively) upon admission. ACTH and cortisol returned to normal ranges on the 2nd day. On the 8th day, an ACTH loading test showed intact cortisol response (peak value 519 nmol/L). However, on the 14th day, there was a sharp decrease in ACTH and cortisol levels (10.5 pmol/L and 47 nmol/L, respectively) accompanied by fatigue and a drop in blood pressure to 97/63 mm Hg. As secondary adrenal insufficiency was suspected, hydrocortisone replacement was initiated. An ACTH loading test on the 17th day revealed low cortisol peak (peak value 232 nmol/L), indicating sudden disruption of adrenal function. Magnetic resonance imaging showed no abnormal findings and there was no other pituitary hormone deficiency. These findings, along with the patient clinical course, suggest that secondary adrenal insufficiency was caused by acute ACTH producing cell destruction as an irAE associated with ICI therapy. Interventions: The patient hyperglycemia and ketoacidosis were treated using extracellular fluid and insulin therapy. After development of adrenal insufficiency, hydrocortisone 20 mg was started, and the patient symptoms improved. Outcomes: He was continued on insulin therapy, hydrocortisone, and reinitiated nivolumab. Lessons: This case provides a detailed course of the fulminant onset of ACTH deficiency during ICI administration, emphasizing the importance of close monitoring.


  • Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas

    by Tomonori Sekizaki, Hiraku Kameda, Akinobu Nakamura, Saki Kuwabara, Hiroshi Nomoto, Kyu Yong Cho, Yukitomo Ishi, Hiroaki Motegi, Hideaki Miyoshi, Tatsuya Atsumi

    Purpose Cushing’s disease (CD) results from autonomous adrenocorticotropic hormone (ACTH) secretion by corticotroph adenomas, leading to excessive cortisol production, ultimately affecting morbidity and mortality. Pasireotide is the only FDA approved tumor directed treatment for CD, but it is effective in only about 25% of patients, and is associated with a high rate of hyperglycemia. Neuromedin B (NMB), a member of the bombesin-like peptide family, regulates endocrine secretion and cell proliferation. Here, we assessed NMB and NMB receptor (NMBR) expression in human corticotroph adenomas and the effects of NMBR antagonist PD168368 on murine and human corticotroph tumors. Methods To investigate NMB and NMBR expression, real-time qPCR and immunostaining on human pathological specimens of corticotroph, non-functional and somatotroph adenomas were performed. The effects of PD168368 on hormone secretion and cell proliferation were studied in vitro, in vivo and in seven patient-derived corticotroph adenoma cells. NMB and NMBR were expressed in higher extent in human corticotroph adenomas compared with non-functional or somatotroph adenomas. Results In murine AtT-20 cells, PD168368 reduced proopiomelanocortin (Pomc) mRNA/protein expression and ACTH secretion as well as cell proliferation. In mice with tumor xenografts, tumor growth, ACTH and corticosterone were downregulated by PD168368. In patient-derived adenoma cells, PD168368 reduced POMC mRNA expression in four out of seven cases and ACTH secretion in two out of five cases. A PD168368-mediated cyclin E suppression was also identified in AtT-20 and patient-derived cells. Conclusion NMBR antagonist represents a potential treatment for CD and its effect may be mediated by cyclin E suppression.


  • Open Access

    Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis

    by Hiroshi Nomoto, Yuka Takahashi, Yoshinari Takano, Hiroki Yokoyama, Kazuhisa Tsuchida, So Nagai, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, et al.

    Non-alcoholic fatty liver disease (NAFLD) is an important common comorbidity in individuals with type 2 diabetes (T2DM). Although some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have beneficial effects on NAFLD, the efficacy of once-weekly semaglutide has not been established. This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks. This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30]. In total, 58 participants met the criteria of this subanalysis. There were no statistical differences in baseline characteristics between the SWITCH (n = 31) and Continue groups (n = 27). FLI significantly improved during treatment in the SWITCH group (68.6 to 62.7) but not in the Continue group (71.1 to 72.3) (p < 0.01). The improvement of FLI in the SWITCH group was greater in switching from dulaglutide to semaglutide and significantly correlated with older age (p = 0.016) and lower baseline FLI (p < 0.01). The multiple linear regression analysis revealed that the switch from dulaglutide was associated with an improvement in FLI (p = 0.041). Switching from conventional GLP-1RAs to once-weekly semaglutide might be beneficial for individuals with NAFLD complicated with T2DM.


  • Open Access

    Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas

    by Tomonori Sekizaki, Hiraku Kameda, Akinobu Nakamura, Saki Kuwabara, Hiroshi Nomoto, Kyu Yong Cho, Yukitomo Ishi, Hiroaki Motegi, Hideaki Miyoshi, Tatsuya Atsumi

    Purpose Cushing’s disease (CD) results from autonomous adrenocorticotropic hormone (ACTH) secretion by pituitary corticotroph adenomas, leading to excessive cortisol production, ultimately affecting morbidity and mortality. Pasireotide is the only FDA approved tumor directed treatment for CD, but it is effective in only about 25% of patients, and is associated with a high rate of hyperglycemia. Neuromedin B (NMB), a member of the bombesin-like peptide family, regulates endocrine secretion and cell proliferation. Here, we assessed NMB and NMB receptor (NMBR) expression in human corticotroph adenomas and the effects of NMBR antagonist PD168368 on murine and human corticotroph tumors.Methods To investigate NMB and NMBR expression, real-time qPCR and immunostaining on human pathological specimens of corticotroph, non-functional and somatotroph pituitary adenomas were performed. The effects of PD168368 on hormone secretion and cell proliferation were studied in vitro, in vivo and in seven patient-derived corticotroph adenoma cells. NMB and NMBR were expressed in higher extent in human corticotroph adenomas compared with non-functional or somatotroph adenomas.Results In murine AtT-20 cells, PD168368 reduced proopiomelanocortin (Pomc) mRNA/protein expression and ACTH secretion as well as cell proliferation. In mice with tumor xenografts, tumor growth, ACTH and corticosterone were downregulated by PD168368. In patient-derived adenoma cells, PD168368 reduced POMC mRNA expression in four out of seven cases and ACTH secretion in two out of five cases. A PD168368-mediated cyclin E suppression was also identified in AtT-20 and patient-derived cells.Conclusion NMBR antagonist represents a potential treatment for CD and its effect may be mediated by cyclin E suppression.